Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 51

1.

N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.

Martin SK, Banuelos CA, Sadar MD, Kyprianou N.

Mol Oncol. 2014 Nov 15. pii: S1574-7891(14)00263-4. doi: 10.1016/j.molonc.2014.10.014. [Epub ahead of print]

PMID:
25432105
2.

Characterization of niphatenones that inhibit androgen receptor N-terminal domain.

Banuelos CA, Lal A, Tien AH, Shah N, Yang YC, Mawji NR, Meimetis LG, Park J, Kunzhong J, Andersen RJ, Sadar MD.

PLoS One. 2014 Sep 30;9(9):e107991. doi: 10.1371/journal.pone.0107991. eCollection 2014.

3.

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD.

J Clin Invest. 2013 Jul;123(7):2948-60. doi: 10.1172/JCI66398. Epub 2013 Jun 3.

4.

Spongian diterpenoids inhibit androgen receptor activity.

Yang YC, Meimetis LG, Tien AH, Mawji NR, Carr G, Wang J, Andersen RJ, Sadar MD.

Mol Cancer Ther. 2013 May;12(5):621-31. doi: 10.1158/1535-7163.MCT-12-0978. Epub 2013 Feb 26.

5.

Large scale phosphoproteome analysis of LNCaP human prostate cancer cells.

Myung JK, Sadar MD.

Mol Biosyst. 2012 Aug;8(8):2174-82. doi: 10.1039/c2mb25151e. Epub 2012 Jun 14.

6.

Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity.

Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, Park JJ, Tien AH, Fernandez JG, de Voogd NJ, Sadar MD, Andersen RJ.

J Med Chem. 2012 Jan 12;55(1):503-14. doi: 10.1021/jm2014056. Epub 2011 Dec 28.

PMID:
22148427
7.

FUS/TLS is a co-activator of androgen receptor in prostate cancer cells.

Haile S, Lal A, Myung JK, Sadar MD.

PLoS One. 2011;6(9):e24197. doi: 10.1371/journal.pone.0024197. Epub 2011 Sep 1.

8.

Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.

Sadar MD.

World J Urol. 2012 Jun;30(3):311-8. doi: 10.1007/s00345-011-0745-5. Epub 2011 Aug 11. Review.

PMID:
21833557
9.

Androgen receptor and its splice variants in prostate cancer.

Haile S, Sadar MD.

Cell Mol Life Sci. 2011 Dec;68(24):3971-81. doi: 10.1007/s00018-011-0766-7. Epub 2011 Jul 12. Review.

10.

Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.

Sadar MD.

Cancer Res. 2011 Feb 15;71(4):1208-13. doi: 10.1158/0008-5472.CAN_10-3398. Epub 2011 Feb 1. Review.

11.

LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.

Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD.

BMC Med Genomics. 2010 Sep 24;3:43. doi: 10.1186/1755-8794-3-43.

12.

Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor.

Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW, Squire JA, Wang Y.

Prostate. 2010 Nov 1;70(15):1636-44. doi: 10.1002/pros.21199.

PMID:
20564316
13.

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, BaƱuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD.

Cancer Cell. 2010 Jun 15;17(6):535-46. doi: 10.1016/j.ccr.2010.04.027.

14.

Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer.

Chiu HH, Yong TM, Wang J, Wang Y, Vessella RL, Ueda T, Wang YZ, Sadar MD.

Cancer Lett. 2010 Jun 28;292(2):176-85. doi: 10.1016/j.canlet.2009.11.023. Epub 2009 Dec 30.

15.

Novel biomarkers for prostate cancer including noncoding transcripts.

Romanuik TL, Ueda T, Le N, Haile S, Yong TM, Thomson T, Vessella RL, Sadar MD.

Am J Pathol. 2009 Dec;175(6):2264-76. doi: 10.2353/ajpath.2009.080868. Epub 2009 Nov 5.

16.

Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries.

Romanuik TL, Wang G, Holt RA, Jones SJ, Marra MA, Sadar MD.

BMC Genomics. 2009 Oct 15;10:476. doi: 10.1186/1471-2164-10-476.

17.

Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection.

Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, McWilliams A, Man SF, Lam S.

J Clin Oncol. 2009 Jun 10;27(17):2787-92. doi: 10.1200/JCO.2008.19.4233. Epub 2009 May 4.

18.

Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.

Wang G, Haile S, Comuzzi B, Tien AH, Wang J, Yong TM, Jelescu-Bodos AE, Blaszczyk N, Vessella RL, Masri BA, Sadar MD.

Cancer Res. 2009 Apr 15;69(8):3433-42. doi: 10.1158/0008-5472.CAN-08-3506. Epub 2009 Apr 7.

19.

Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.

Wang G, Wang J, Sadar MD.

Cancer Res. 2008 Dec 1;68(23):9918-27. doi: 10.1158/0008-5472.CAN-08-1718.

20.

Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells.

Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, Chasanah E, Irianto HE, Soest RV, Andersen RJ.

Org Lett. 2008 Nov 6;10(21):4947-50. doi: 10.1021/ol802021w. Epub 2008 Oct 4.

PMID:
18834139
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk